Annovis Bio earnings release, May 15, 2026

Annovis Bio, Inc. (ANVS) · Form 8-K, Item 2.02 · Filed · SEC filing

Annovis

Provides Corporate Updates and Reports First Quarter 2026 Financial Results

Malvern, PA, May 15, 2026 -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided business updates and reported financial results for the first quarter ended March 31, 2026.

"We saw strong momentum across both our AD and PD programs in the first quarter," said Maria Maccecchini, Ph.D., President and CEO of Annovis. “Our Phase 3 AD clinical trial achieved significant enrollment growth, keeping us firmly on track to complete randomization of patients in summer 2026 and deliver first top-line results in early 2027. Simultaneously, we launched a PD OLE study and have been encouraged by the robust interest from both returning and new patients. This year is pivotal: we expect to generate substantive clinical data across both indications that will anchor our regulatory path toward an NDA submission for buntanetap."

Clinical highlights

Alzheimer’s disease – pivotal Phase 3 trial (NCT06709014)

Parkinson’s disease – OLE study (NCT07284784)

Corporate highlights

Upcoming milestones

Financial results

About Annovis

Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on

LinkedIn,

YouTube, and

X.

Investor Alerts

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.

Financial statements

Income Statement

Three Months Ended — Statements of Operations

Three Months Ended – March 31, – 2026Three Months Ended – March 31, – 2025
Operating expenses:Research and development16,720,3625,011,517
Operating expenses:General and administrative1,291,8201,271,164
Operating expenses:Total operating expenses18,012,1826,282,681
Operating expenses:Operating loss-18,012,182-6,282,681
Other income:Interest income137,800187,612
Other income:Change in fair value of warrants (Note 7)268,000558,000
Other income:Total other income, net405,800745,612
Other income:Net loss-17,606,382-5,537,069
Net loss per share (Note 9)Basic-0.63-0.32
Net loss per share (Note 9)Diluted-0.63-0.32
Weighted-average number of common shares used in computing net loss per shareBasic27,847,88417,431,234
Weighted-average number of common shares used in computing net loss per shareDiluted27,847,88417,431,234

Balance Sheet

Balance Sheets

March 31, – 2026 – (Unaudited)December 31, – 2025
Current assets:Cash and cash equivalents14,219,08119,532,338
Current assets:Prepaid expenses and other current assets2,024,6221,549,287
Current assets:Total assets16,243,70321,081,625
Current liabilities:Accounts payable5,275,6682,590,516
Current liabilities:Accrued expenses7,514,9771,044,859
Current liabilities:Total current liabilities12,790,6453,635,375
Non-current liabilities:Warrant liability327,000595,000
Non-current liabilities:Total liabilities13,117,6454,230,375
Stockholders’ equity:Common stock - $0.0001 par value, 70,000,000 shares authorized, 28,537,302 and 27,199,139 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively2,8542,719
Stockholders’ equity:Additional paid-in capital184,433,245180,552,190
Stockholders’ equity:Accumulated deficit-181,310,041-163,703,659
Stockholders’ equity:Total stockholders’ equity3,126,05816,851,250
Stockholders’ equity:Total liabilities and stockholders’ equity16,243,70321,081,625
Full release

Forward-Looking Statements

This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact Information:

Annovis Bio Inc.

101 Lindenwood Drive

Suite 225

Malvern, PA 19355 www.annovisbio.com

Investor Contact:

Alexander Morin, Ph.D.

Director, Strategic Communications

Annovis Bio ir@annovisbio.com

(Tables to follow)

ANNOVIS BIO, INC.

Balance Sheets

ANNOVIS BIO, INC.

Statements of Operations

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Annovis Bio earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.